Onkologie. 2017:11(2):66-71 | DOI: 10.36290/xon.2017.014

Anti-EGFR therapy in colorectal carcinoma

Stanislav Batko
Onkologická klinika 2. LF UK a FN Motol, Praha

Metastatic colorectal carcinoma is among the most common tumour diseases and is a major contributor to the overall death rate from

tumour diseases. The introduction of anti-VEGF and anti-EGFR monoclonal antibodies in 2004 was a milestone in treating metastatic

colorectal carcinoma that has led to a significantly improved prognosis in metastatic disease. The discovery of novel predictive markers

has resulted in better selection of patients who can benefit from this treatment, and thus in a broader fulfilment of the purpose of targeted

and tailored therapy. The present article deals with a brief history of development of anti-EGFR therapy in colorectal carcinoma.

Keywords: BRAF, cetuximab, EGFR, colorectal carcinoma, panitumumab, RAS

Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Batko S. Anti-EGFR therapy in colorectal carcinoma. Onkologie. 2017;11(2):66-71. doi: 10.36290/xon.2017.014.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Torre LA, Global cancer statistics, 2012, CA Cancer J Clin. 2015; 65(2): 87-108. Go to original source... Go to PubMed...
    2. Zdravotnictví ČR: Nová data Národního onkologického registru ČR (NOR) za rok 2014 NZIS Report č. R/1 (09/2016) dostupné z www.uzis.cz/system/files/NZIS_REPORT_c_R01_09_16_NOR_0.pdf
    3. Francis Edwin. A Historical Perspective of the EGF Receptor and Related Systems, Methods Mol Biol. 2006; 327: 1-24. Go to original source... Go to PubMed...
    4. Morley D. Hollenberg and Pedro Cuatrecasas, Epidermal Growth Factor: Receptors in Human Fibroblasts and Modulation of Action by Cholera Toxin, Proc Natl Acad Sci U S A. 1973; 70(10): 2964-2968. Go to original source... Go to PubMed...
    5. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy, Endocrine-Related Cancer 2001; 8: 3-9. Go to original source... Go to PubMed...
    6. Hemming AW. Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki-67, Journal of Surgical Oncology. November 1992; 51(3): 147-152. Go to original source... Go to PubMed...
    7. Waugh MG, Hsuan JJ. EGF receptors as transcription factors: ridiculous or sublime? Nat Cell Biol 2001; 3: E209-11. Go to original source... Go to PubMed...
    8. Saltz L, Rubin M, Hochester H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract] Proc Am Soc Clin Oncol. 2001;20 Abstract 7.
    9. Saltz LB, Meropol NJ, Loehrer PJ, Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22: 1201-1208. Go to original source... Go to PubMed...
    10. Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-345. Go to original source... Go to PubMed...
    11. Jonker DJ. Cetuximab for the treatment of colorectal cancer, N Engl J Med. 2007; 357(20): 2040-2048. Go to original source... Go to PubMed...
    12. Tabernero J. Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer, Journal of Clinical. 2007; 25(30): 5225-5232. Go to original source... Go to PubMed...
    13. Van Cutsem E. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer, Journal of Clinical Oncology. 2007; 25(13): 1658-1664. Go to original source... Go to PubMed...
    14. Hebbar M. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer, Anticancer Drugs. 2006; 17(7): 855-857. Go to original source... Go to PubMed...
    15. Chung KY, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry, J Clin Oncol. 2005; 23(9): 1803-1810. Go to original source... Go to PubMed...
    16. Li?vre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995. Go to original source... Go to PubMed...
    17. Capon DJ, Seeburg PH, McGrath JP, et al. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 1983; 304: 507-513. Go to original source... Go to PubMed...
    18. Forrester K, Almoguera C, Han K, et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987; 327: 298-303. Go to original source... Go to PubMed...
    19. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765. Go to original source... Go to PubMed...
    20. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019. Go to original source... Go to PubMed...
    21. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671. Go to original source... Go to PubMed...
    22. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114. Go to original source... Go to PubMed...
    23. Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer:the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-1762. Go to original source... Go to PubMed...
    24. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634. Go to original source... Go to PubMed...
    25. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-4713. Go to original source... Go to PubMed...
    26. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-smallcell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-972. Go to original source... Go to PubMed...
    27. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. Aug 2010; 11(8): 753-762. PMID 20619739 Go to original source... Go to PubMed...
    28. Irahara N, Baba Y, Nosho K, et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. Sep 2010; 19(3): 157-163. PMID 20736745 Go to original source... Go to PubMed...
    29. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol. Jul 2014; 53(7): 852-864. PMID 24666267 Go to original source... Go to PubMed...
    30. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. Mar 2015; 51(5): 587-594. PMID 25673558 29. Go to original source... Go to PubMed...
    31. Mao C, Liao RY, Qiu LX, et al. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep. Apr 2011; 38(4): 2219-2223. PMID 20857202 Go to original source... Go to PubMed...
    32. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. Dec 10 2008; 26(35): 5705-5712. PMID 19001320 Go to original source... Go to PubMed...
    33. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. Dec 10 2009; 27(35): 5924-5930. PMID 19884556 Go to original source... Go to PubMed...
    34. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. Aug 18 2009; 101(4): 715-721. PMID 19603018. Go to original source... Go to PubMed...
    35. Sobrero AF. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol. 2008; 26(14): 2311-2319. Go to original source... Go to PubMed...
    36. Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 2013; 369(11): 1023-1034. Go to original source... Go to PubMed...
    37. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. Go to original source... Go to PubMed...
    38. Heinemann V, von Weikersthal L, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. J Clin Oncol 2014; 15(10): 1065-1075. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.